Acorda Therapeutics (ACORQ)
(Delayed Data from OTC)
$0.07 USD
-0.03 (-30.00%)
Updated Jul 26, 2024 03:29 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Acorda Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 30 | 44 | 59 | 84 | 139 |
Receivables | 17 | 14 | 17 | 20 | 22 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 13 | 19 | 29 | 25 |
Other Current Assets | 11 | 11 | 8 | 88 | 15 |
Total Current Assets | 75 | 82 | 102 | 221 | 201 |
Net Property & Equipment | 2 | 3 | 4 | 7 | 143 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 23 | 305 | 336 | 367 | 402 |
Deposits & Other Assets | 4 | 1 | 6 | 19 | 30 |
Total Assets | 109 | 396 | 455 | 633 | 800 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 186 | 0 | 0 | 69 | 1 |
Accounts Payable | 13 | 10 | 11 | 12 | 26 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 24 | 29 | 38 | 39 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 6 | 10 | 13 |
Total Current Liabilities | 228 | 38 | 54 | 137 | 86 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 27 | 44 | 14 | 19 | 10 |
Convertible Debt | 0 | 167 | 151 | 138 | 193 |
Long-Term Debt | 0 | 0 | 28 | 29 | 26 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 48 | 54 | 55 | 152 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 266 | 302 | 304 | 395 | 489 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,030 | 1,030 | 1,023 | 1,008 | 979 |
Retained Earnings | -1,189 | -936 | -870 | -766 | -667 |
Other Equity | 1 | 1 | -1 | -3 | -1 |
Treasury Stock | 1 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | -158 | 94 | 151 | 238 | 311 |
Total Liabilities & Shareholder's Equity | 109 | 396 | 455 | 633 | 800 |
Total Common Equity | -158 | 94 | 151 | 238 | 311 |
Shares Outstanding | 1.20 | 1.20 | 0.50 | 0.40 | 0.40 |
Book Value Per Share | -131.63 | 78.02 | 302.28 | 594.90 | 777.05 |
Fiscal Year End for Acorda Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 10 | 30 | 33 | 26 |
Receivables | NA | 9 | 17 | 12 | 13 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 14 | 16 | 18 | 15 |
Other Current Assets | NA | 15 | 11 | 10 | 11 |
Total Current Assets | NA | 48 | 75 | 74 | 65 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 22 | 23 | 282 | 290 |
Deposits & Other Assets | NA | 5 | 4 | 4 | 3 |
Total Assets | NA | 82 | 109 | 366 | 365 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 191 | 186 | 0 | 0 |
Accounts Payable | NA | 10 | 13 | 12 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 18 | 24 | 29 | 22 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 2 | 3 | 4 |
Total Current Liabilities | NA | 224 | 228 | 46 | 30 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 27 | 39 | 40 |
Convertible Debt | NA | 0 | 0 | 181 | 176 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 8 | 38 | 47 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 267 | 266 | 307 | 297 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,031 | 1,030 | 1,030 | 1,030 |
Retained Earnings | NA | -1,217 | -1,189 | -971 | -962 |
Other Equity | NA | 1 | 1 | 1 | 1 |
Treasury Stock | NA | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | NA | -186 | -158 | 59 | 68 |
Total Liabilities & Shareholder's Equity | NA | 82 | 109 | 366 | 365 |
Total Common Equity | 0 | -186 | -158 | 59 | 68 |
Shares Outstanding | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
Book Value Per Share | 0.00 | -154.81 | -131.63 | 49.13 | 56.56 |